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inappropriate selection of patients for randomization is the
fact that mortality in the conventional arm was 1/42¼ 2.38%,
which is at least 7 times lower than that in the general
population of hemodialysis (HD) patients in the United States.
Many patients in the control group performed more frequent
dialysis sessions and those in the more frequent group
performed less frequent dialyses. The ultimate conclusion that
was reached was that the frequent nocturnal dialysis study
group had improvement in ‘‘control of hyperphosphatemia
and hypertension but no beneﬁt among other main secondary
outcomes’’. Improvement of left ventricular mass was rejected
as insigniﬁcant on the basis of a P-value of 0.09, which means a
chance difference probability of 1 in 11 instead of 1 in 20. We
wonder whether the Student’s paired t-test, if performed in
the patients in the ‘frequent group’, would show that a
decrease of left ventricular mass from an average of 141 to 132
was in fact statistically signiﬁcant. In all, this study committed
a type II statistical error because of the evidently small
number and inappropriate selection of subjects. On the basis
of this study it absolutely cannot be accepted that frequent
nocturnal HD is not better than conventional thrice-weekly
HD. Interestingly, the front page of Kidney International
egregiously highlights the rather misperceived notion that
frequent nocturnal HD is of no beneﬁt!
1. Rocco MV, Lockridge RS, Beck GJ et al. The effects of frequent nocturnal
home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Kidney Int 2011; 80: 1080–1091.
2. Twardowski Z. Significance of certain measurable parameters in
the evaluation of haemodialysis adequacy. Acta Med Pol 1974; 15:
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The Authors Reply: Drs Misra and Twardowski1 claim that
subjects in the Frequent Hemodialysis Network (FHN)
Nocturnal Trial2 were inappropriately selected. All rando-
mized subjects in the Nocturnal Trial had stage V chronic
kidney disease and o20% of subjects had a urea clearance
43ml/min. Although the mortality rate in both the FHN
Daily and Nocturnal Trials was lower than that seen in the
general hemodialysis population, this observation is common
to randomized clinical trials and is likely due to the exclusion
of subjects with a limited life expectancy who would not be
inﬂuenced by the intervention. Less than 10% of subjects in
the control arm performed dialysis X4 times per week
(Figure 2)2 and 72% of subjects in the more frequent arm had
X4.8 treatments per week (Table 2).2 In addition, the separa-
tion in the weekly dose of dialysis between arms was robust
(total weekly standard Kt/Vurea of 5.03±1.23 vs. 2.91±0.86,
Po0.001). While our ﬁndings for left ventricular mass (LVM)
did not achieve statistical signiﬁcance, the mean change and
95% conﬁdence intervals for LVM were not materially
different from the results of the FHN Daily Trial.3 We
provided several possible explanations for the non-signiﬁcant
effect of more frequent dialysis on LVM in our discussion,2 as
did Davenport in his commentary.4 Finally, the summary
statement on the front cover was not written by the authors
but was provided by the Kidney International staff. We did
not conclude that there is no beneﬁt of nocturnal dialysis
on LVM.
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Implausible similarities in patient
characteristics between two
randomized controlled studies: a
coincidence is unlikely
To the Editor: We have read the interesting article of the
randomized controlled trial (RCT) by Goraya et al.1 showing
that 30-day dietary acid reduction with an aggressive intake of
fruits and vegetables (FþV) has a renoprotective effect for stage
2 chronic kidney disease (CKD). Despite the small sample
size, it clearly demonstrated the efﬁcacy of FþV by both
clinical and experimental surrogate markers. Its effect is
almost the same with that of sodium bicarbonate, which had
already been shown to attenuate the rate of decline of the
glomerular ﬁltration rate in a 5-year RCT by the same group
of this study.2 Thus, FþV without the increase in sodium
intake may be more favorable than sodium bicarbonate for
early CKD patients.
However, the characteristics of the participants with
stage 2 CKD between these two RCTs are implausibly
similar (Table 1). These similarities are impossible for two
separate RCTs with at least a 5-year interval. Even if these
studies were conducted in parallel without a detailed
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description, the ‘NaCl’ groups should not be considered
as the control, and ‘FþV’ seems like placebo with 5-year
observation.
The long-term follow-up of the MDRD study revealed the
risk of the low-protein diet,3 which has been believed to be
good for CKD by both patients and health professionals
for a long time. The interesting hypothesis of Goraya et al. could
have been an alternative dietary intervention for CKD
patients if proven appropriately. Disappointingly, the serious
suspicion of faking research has made a mess of the series of
their RCTs.
1. Goraya N, Simoni J, Jo C et al. Dietary acid reduction with fruits and
vegetables or bicarbonate attenuates kidney injury in patients with a
moderately reduced glomerular filtration rate due to hypertensive
nephropathy. Kidney Int 2012; 81: 86–93.
2. Mahajan A, Simoni J, Sheather SJ et al. Daily oral sodium bicarbonate
preserves glomerular filtration rate by slowing its decline in early
hypertensive nephropathy. Kidney Int 2010; 78: 303–309.
3. Menon V, Kopple JD, Wang X et al. Effect of a very low-protein diet on
outcomes: long-term follow-up of the Modification of Diet in Renal Disease
(MDRD) Study. Am J Kidney Dis 2009; 53: 208–217.
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The Authors Reply: We thank Dr Obi et al. for their
comment1 regarding similarities in subject groups in our two
Kidney International publications2,3 and their question of
whether the two studies are truly randomized controlled
studies given that some groups across the studies are very
similar. Since 1999 we serially recruited subjects with
hypertensive nephropathy and various estimated glomerular
ﬁltration rate (eGFR) levels to test the hypothesis that dietary
acid reduction reduces acid retention,4 reduces kidney injury,2
and slows eGFR decline.3 Subjects were recruited and serially
entered into protocols designed to test these hypotheses. The
ﬁrst protocol randomized three sets of subjects with stage 2
eGFR, each of whom underwent three serial stages of studies
to assess the effect of dietary acid reduction on acid retention
(baseline and after 30 days), kidney injury (before and after
30 days), and, after a 30-day washout, the effect on eGFR after
5 years. Each subject was followed up in excess of 5 years, but
in each case the follow-up began at recruitment and study
entry. Speciﬁcally, they were not recruited as a group and then
followed as a group at the same time. We initially submitted
one manuscript to Kidney International that included the
described three serial stages of study done on each subject to
test all the three hypotheses. The Editors asked that we not
test all the three hypotheses in a single manuscript, but to do
so in separate manuscripts. We chose ﬁrst to submit a
manuscript detailing the main, randomized protocol in these
stage 2 subjects that showed long-term (5-year) effects on
eGFR3 followed by separate submissions of the shorter-term
portions of this protocol in many of the same subjects that
examined the effects on acid retention4 and, most recently,
kidney injury.2 Consequently, some subject groups that were
randomized for the 5-year protocol to examine the effects of
the interventions on eGFR were the same groups used to test
the two remaining hypotheses as described but were not
further randomized.
1. Obi Y, Hama H, Suzuki Y et al. Implausible similarities in patient
characteristics between two randomized controlled studies: a coincidence
is unlikely. Kidney Int 2012; 82: 115–116.
Table 1 | Common patient characteristics quoted from the reports by Goraya et al.1 and Mahajan et al.2
Goraya et al.,
CKD2 control
(n=40)
Mahajan
et al., NaCl
(n=40)
Goraya et al.,
CKD2 and HCO3
(n=40)
Mahajan
et al., NaHCO3
(n=40)
Goraya et al.,
CKD2 and F+V
(n=40)
Mahajan
et al., placebo
(n=40)
Males (%) 47.5 48 47.5 48 47.5 48
Black/white/Hispanic (%) 62.5/22.5/15.0 63/23/15 62.5/20.0/17.5 63/20/18 62.5/25.0/12.5 63/25/13
Age (years) 51.5±8.3 51.5±8.3 51.2±8.2 51.2±8.2 51.3±8.5 51.3±8.5
Systolic BP (mm Hg) 134.3±8.3 152.6±14.7 134.1±5.8 155.3±12.6 133.7±8.6 155.2±12.9
eGFR (ml/min) 75.6±6.5 75.6±6.5 75.3±6.1 75.3±6.1 75.6±6.2 75.6±6.2
Plasma total CO2 (mmol/l) 26.0±0.8 26.4±0.8 25.9±0.6 26.2±0.7 25.9±0.8 26.0±0.9
PRAL (mmol/day) 59.3±21.1 59.3±21.1 64.3±17.7 64.3±17.7 60.4±19.4 60.4±19.4
8-h NAE (mEq) 24.6±5.7 24.8±6.4 24.8±5.6 24.8±5.6 24.6±5.0 24.0±5.6
Ualb (mg/g Cr) 413.6±147.9 413.6±147.9 419.3±150.8 419.3±150.8 422.2±151.6 422.2±151.6
UNAG (U/g Cr) 2.7±0.4 2.6±0.5 2.7±0.4 2.7±0.4 2.7±0.7 2.7±0.7
UET-1 (ng/g Cr) 5.5±1.1 5.7±0.8 5.7±1.0 5.7±1.0 5.5±1.2 5.5±1.2
Urine Na+ excretion (mmol/g Cr) 71.6±7.9 70.6±10.2 70.9±10.2 70.9±10.2 73.0±9.5 73.0±9.5
Urine K+ excretion (mmol/g Cr) 38.6±5.5 38.2±6.2 41.1±6.1 41.1±6.1 39.5±6.6 39.5±6.6
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; F+V, fruits and vegetables; NAE, net acid excretion;
PRAL, potential renal acid load; Ualb, urine albumin-to-creatinine ratio; UET-1, urine endothein-1-to-creatinine ratio; UNAG, urine N-acetyl-b-D-glucosaminidase-to-creatinine ratio.
Values are expressed as number, percentage, or mean±SD as appropriate.
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